Mondolfi Alberto Paniz, Singh Rajesh R
Microbiology Laboratory, Department of Laboratory Medicine,Yale New Haven Hospital, Yale University School of Medicine, New Haven, CT, USA.
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 8515 Fannin Street, Houston, TX, 77054, USA.
Methods Mol Biol. 2016;1392:83-101. doi: 10.1007/978-1-4939-3360-0_9.
Over the last decade, cancer genome sequencing has revealed in detail the genomic landscapes of an increasing number of common solid human tumors. This has greatly impacted the clinical care of cancer patients based on the fact that many of these tumors exhibit activating mutations in driver genes that are prone to target therapy, largely impacting cancer management strategies. Genomic heterogeneity of tumors is becoming an increasingly recognized phenomenon relevant to genome-based medicine. Because a large number tumors may display several mutations at the same time, multiplexing has become the preferred approach to reveal the mutational landscape in patient samples and to better design a targeted approach to their illness.